Education
About Us
Working with TipRanks
Follow Us
Gain Therapeutics, Inc. (GANX)
NASDAQ:GANX
GANX Stock Chart & Stats
$1.81
-$0.01(-0.44%)
At close: 4:00 PM EST
$1.81
-$0.01(-0.44%)
Day’s Range― - ―
52-Week Range$1.41 - $4.34
Previous CloseN/A
Volume74.47K
Average Volume (3M)1.82M
Market Cap
$69.62M
Enterprise Value$0.00
Total Cash (Recent Filing)$8.81M
Total Debt (Recent Filing)$180.94K
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Mar 19, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding38,462,086
10 Day Avg. Volume1,501,087
30 Day Avg. Volume1,819,161
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)6.73
Price to Sales (P/S)0.00
P/FCF Ratio-2.62
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$7.50Price Target Upside314.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker EvidencePrespecified exploratory data showed reductions in cerebrospinal fluid glucosylsphingosine, supporting central nervous system target engagement and validation of the drug's intended mechanism.
Clinical Development ProgressA completed Investigational New Drug filing enables expansion into a later-stage clinical trial and planned patient enrollment, clearing a regulatory hurdle for further development.
Tolerability And RetentionAll participants entered the extension phase, indicating favorable tolerability and strong patient retention that supports continued clinical evaluation.
Bears Say
Market Volatility And Financing RiskShares experienced pronounced volatility around the data release, reflecting profit-taking and market expectations of a capital raise that could increase dilution risk.
Study Design And Sample SizeThe early-stage, open-label study was small and uncontrolled, so the observed findings are preliminary and require confirmation in randomized trials.
Uncertain Translation To Clinical BenefitBiomarker improvements have not yet been linked to consistent patient-level clinical benefits, and individual clinical endpoints were noisy.
Gain Therapeutics News
GANX FAQ
What was Gain Therapeutics, Inc.’s price range in the past 12 months?
Gain Therapeutics, Inc. lowest stock price was $1.41 and its highest was $4.34 in the past 12 months.
What is Gain Therapeutics, Inc.’s market cap?
Gain Therapeutics, Inc.’s market cap is $69.62M.
When is Gain Therapeutics, Inc.’s upcoming earnings report date?
Gain Therapeutics, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 59 days.
How were Gain Therapeutics, Inc.’s earnings last quarter?
Gain Therapeutics, Inc. released its earnings results on Nov 12, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.161 by $0.011.
Is Gain Therapeutics, Inc. overvalued?
According to Wall Street analysts Gain Therapeutics, Inc.’s price is currently Undervalued.
Does Gain Therapeutics, Inc. pay dividends?
Gain Therapeutics, Inc. does not currently pay dividends.
What is Gain Therapeutics, Inc.’s EPS estimate?
Gain Therapeutics, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Gain Therapeutics, Inc. have?
Gain Therapeutics, Inc. has 38,462,086 shares outstanding.
What happened to Gain Therapeutics, Inc.’s price movement after its last earnings report?
Gain Therapeutics, Inc. reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.161. Following the earnings report the stock price went up 10.075%.
Which hedge fund is a major shareholder of Gain Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gain Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (314.36% Upside)
$7.50 (314.36% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.62%
12-Months-Change
Fundamentals
Return on Equity
-261.72%
Trailing 12-Months
Asset Growth
-23.63%
Trailing 12-Months
Company Description
Gain Therapeutics, Inc.
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
GANX Stock 12 Month Forecast
Average Price Target
$7.50
▲(314.36% Upside)
Technical Analysis
Plus Therapeutics
―
ABVC BioPharma
―
PMV Pharmaceuticals
―
Prelude Therapeutics
―
Immix Biopharma
―
Ownership Overview
3.33%
Insiders
1.66% Mutual Funds
0.10% Other Institutional Investors
93.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---